Results 251 to 260 of about 1,090,016 (327)

Accumulating Genetic Mutations from Primary to Secondary Biliary Tract Cancers: Analysis of Four Patients With Metachronous Biliary Tract Cancer Using Comprehensive Genomic Profiling. [PDF]

Cancer Genomics Proteomics
Kokuryo T, Koike Y, Yamaguchi J, Sunagawa M, Baba T, Watanabe N, Onoe S, Mizuno T, Ebata T.   +8 more
europepmc   +1 more source

Extrahepatic biliary tract obstruction due to foreign body in a dog.

, 2016
S. H. Yun, S. J. Lee, M. R. Kim, Yeongkeun Kwon   +3 more
openalex   +1 more source

Global burden of early-onset gallbladder and biliary tract cancer from 1990 to 2021. [PDF]

BMC Gastroenterol
Liu J, Fang W, He X, Zhang X, Liu H.
europepmc   +1 more source

Utility of a novel tapered-tip sheath system for preoperative mapping biopsy of biliary tract cancers. [PDF]

Endosc Int Open
Matsumori T, Uza N, Okada K, Shiokawa M, Maruno T, Nishikawa Y, Kuwada T, Muramoto Y, Yasuda M, Yamazaki H, Taura K, Hatano E, Kodama Y, Seno H.   +13 more
europepmc   +1 more source

The real-world clinical effectiveness of durvalumab in advanced biliary tract cancer: a mimic comparative analysis through survival data reconstruction. [PDF]

Front Immunol
Ji HX, Si MH, Sun Z, Yang N, Chen Z.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Biliary tract cancer

The Lancet, 2021
Biliary tract cancers, including intrahepatic, perihilar, and distal cholangiocarcinoma as well as gallbladder cancer, are low-incidence malignancies in most high-income countries, but represent a major health problem in endemic areas; moreover, the incidence of intrahepatic cholangiocarcinoma is rising globally. Surgery is the cornerstone of cure; the
Juan W, Valle, R Katie, Kelley, Bruno, Nervi, Do-Youn, Oh, Andrew X, Zhu   +4 more
openaire   +3 more sources

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

NEJM Evidence, 2022
Durvalumab Combination for Biliary Tract CancerThis trial randomly assigned patients with previously untreated locally advanced or metastatic biliary tract cancer to receive durvalumab or placebo in combination with gemcitabine plus cisplatin.
D. Oh, A. Ruth He, S. Qin, Li‐Tzong Chen, T. Okusaka, A. Vogel, J. W. Kim, T. Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, H. Burris, M. Bouattour, S. Tanasanvimon, M. McNamara, R. Zaucha, A. Avallone, Benjamin Tan, Juan Cundom, Choong-kun Lee, Hidenori Takahashi, M. Ikeda, Jen‐Shi Chen, Julie Wang, M. Makowsky, N. Rokutanda, P. He, J. Kurland, G. Cohen, J. Valle   +28 more
semanticscholar   +1 more source

Increasing gallstone disease prevalence and associations with gallbladder and biliary tract mortality in the US

Hepatology, 2023
Background and Aims: We examined gallbladder and biliary tract mortality predictors in the US National Health and Nutrition Examination Survey (NHANES), 1988-1994, with 31 years of linked mortality data, and gallstone disease prevalence trends and ...
A. Unalp-arida, C. Ruhl
semanticscholar   +1 more source